The first all-oral AML regimen: oral decitabine plus venetoclax

For older adults with newly diagnosed acute myeloid leukemia, the standard of care since 2020 has been a hypomethylating agent plus venetoclax. It works, but the hypomethylating agent has always been an injection, which means recurring clinic visits for a population that is frail by definition. On 13 May 2026 the FDA approved oral decitabine/cedazuridine (INQOVI) in combination with venetoclax, making the entire frontline regimen a pill. It is a small-molecule story worth understanding, because both halves are textbook examples of how chemistry solves a clinical problem.

Why the regimen needed an oral hypomethylating agent

Decitabine is a cytidine analog that incorporates into DNA and covalently traps DNA methyltransferase, stripping the aberrant methylation that silences tumor-suppressor genes in AML. The problem has never been the mechanism. It is the pharmacokinetics: decitabine is destroyed almost instantly by cytidine deaminase (CDA), an enzyme highly expressed in the gut and liver. Swallow it on its own and first-pass metabolism leaves essentially nothing for the marrow. That is why decitabine spent two decades as an intravenous or subcutaneous drug.

Cedazuridine: a deaminase inhibitor as a pharmacokinetic enabler

Cedazuridine is the clever part. It is a tetrahydrouridine-derived cytidine deaminase inhibitor (IC50 around 0.28 uM) with far better chemical stability than tetrahydrouridine itself. Taken with oral decitabine, it blocks CDA in the gut and liver long enough for the decitabine to survive first pass and reach therapeutic AUC exposures that match the IV dose milligram-for-milligram. There is also evidence that cedazuridine engages the concentrative nucleoside transporter CNT1 in the kidney and slows renal clearance of decitabine, adding to the exposure benefit. The fixed-dose oral combination (35 mg decitabine / 100 mg cedazuridine) was first approved in MDS in 2020; the 2026 decision extends it into AML in combination with venetoclax.

Venetoclax: a BH3-mimetic that restores apoptosis

Venetoclax is the small molecule that made BCL2 druggable. AML blasts, especially in older patients, lean heavily on the anti-apoptotic protein BCL2 to evade programmed cell death. BCL2 works by sequestering pro-apoptotic effectors through its hydrophobic BH3-binding groove. Venetoclax is a BH3 mimetic: it occupies that groove, displaces the sequestered pro-death proteins, and lets the cell execute apoptosis. It is a hard target for structure-based design because the groove is a shallow, extended protein-protein interaction surface rather than a deep enzyme pocket, which is exactly why venetoclax is such a large, elaborated molecule.

What the data showed

• VIALE-A (2020) established the combination logic: azacitidine plus venetoclax delivered median overall survival of 14.7 months versus 9.6 months for azacitidine alone, with a composite complete-remission rate of 66.4% versus 28.3%. This is the benchmark the oral regimen is built to reproduce without the injections.
• ASCERTAIN-V (the registrational study for the 2026 approval) tested oral decitabine/cedazuridine plus venetoclax in newly diagnosed AML patients ineligible for intensive induction. Among efficacy-evaluable patients, 41.6% achieved a complete remission, median time to CR was about 2 months, and 75.3% of responders were still in remission at 12 months.

The clinical significance is logistical as much as pharmacological: for a 75-plus patient who may live far from a treatment center, the difference between an injectable and an all-oral regimen can decide whether they get treated at all.

Try the docking yourself

BCL2 is the structurally interesting target here. The canonical venetoclax co-crystal is 6O0K, with venetoclax bound in the BH3 groove. Open Studio and pick BCL2 to run molecular docking against the same groove and see why a shallow protein-protein interface forces such a large ligand. Liganx is molecular docking online, free and browser-based, so you can explore the BH3-mimetic pose without a local install.

Primary sources

• DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383, 617-629 (2020). doi:10.1056/NEJMoa2012971
• Dhillon S. Decitabine/Cedazuridine: First Approval. Drugs 80, 1373-1378 (2020). PMC7708383
• Taiho Oncology. U.S. FDA Approves INQOVI in Combination with Venetoclax, the First All-Oral Combination Treatment for AML Patients Ineligible for Intensive Induction Chemotherapy. Press release, 13 May 2026. businesswire.com